Clinical Trials
17 trialsNCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05609942 2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT04722601 2024-05-16
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
University of Chicago
Phase 1/2 Terminated
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT03465540 2023-04-12
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
Phase 1 Terminated
NCT01241786 2022-07-20
VZCLLPI0146
Hackensack Meridian Health
Phase 2 Terminated
NCT02587598 2021-12-08
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT02750254 2020-10-20
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
Phase 1 Terminated
NCT01747499 2019-10-16
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Washington University School of Medicine
Phase 1/2 Terminated
NCT01121757 2016-09-12
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Duke University
Phase 2 Terminated
NCT01908387 2015-07-28
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Phase 1 Terminated
NCT00543582 2015-07-01
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00413478 2015-06-30
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated